Regulatory approval

HRR Testing Moves Upfront in Prostate Cancer
FDA has moved talazoparib plus enzalutamide into metastatic androgen pathway modulation-naive or sensitive prostate cancer with HRR mutations. Molecular profiling can no longer be treated as a later-line exercise when it now determines first-line metastatic treatment.

FDA Redraws the TMB-High Treatment Line

CLL Just Moved a Noncovalent BTK Inhibitor Into First Line

Kidney Cancer Has a New Post-Immunotherapy Standard. Survival Is Not Settled.

Kidney Cancer Has a New Post-Immunotherapy Standard. Survival Is Not Settled.

Cholangiocarcinoma Just Made FGFR2 Testing Harder to Ignore

SMA Treatment Finally Reaches the Muscle

HER2-Mutant Lung Cancer Just Moved Into First Line

Brain Cancer Finally Gets the PET Scan It Has Been Missing

Alzheimer’s PET Is Becoming Data Infrastructure
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
